Aurobindo Pharma Q1 Results FY26: Q1 PAT Narrows 10.28% to ₹824.75 Crore; Revenue Surged 3.98% YoY

Aurobindo Pharma Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)

Particulars	Quarter Ended
	30-06-2025	30-06-2024
Revenue from Operations	₹7,868.14	₹7,567.02
Profit Before Tax (PBT)	₹1,708.33	₹1,840.50
Profit After Tax (PAT)	₹824.75	₹919.22

(Figures in crores)

Aurobindo Pharma Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

Particulars	Quarter Ended
	30-06-2025	30-06-2024
Revenue from Operations	₹2,848.17	₹2,460.09
Profit Before Tax (PBT)	₹880.11	₹564.25
Profit After Tax (PAT)	₹559.13	₹329.04

(Figures in crores)

Aurobindo Pharma Q1 Results FY26 Highlights (Q1 FY26 vs FY25)

• Aurobindo Pharma clocked Q1 FY26 consolidated revenue of ₹7,868.14 crores vs ₹7,567.02 crores. 
• On the profit front, Aurobindo Pharma earned a consolidated PAT of ₹824.75 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹919.22 crore. 
• Consolidated PAT fell for the first quarter of FY26, was 10.28% YoY, and revenue rose 3.98% YoY. 
• As per the standalone figures, the quarterly PAT of Aurobindo Pharma has increased by 69.93% and revenue has increased by 15.78% YoY.

Aurobindo Pharma Share Price Performance

On the opening bell of 5th August 2025, the shares of Aurobindo Pharma opened at ₹1,073.10 per share. However, the initial gains are sustained as of now, and Aurobindo Pharma shares are trading at ₹1,076.00 per share, higher than their opening price. 

Considering the long-term performance, Aurobindo Pharma shares have yielded close to -24.29% returns in the past 1 year, and 5-year returns stand at 18.70%. Over the maximum timeframe, the Aurobindo Pharma share provided 23,026.88% returns to investors. However, one must ignore the risk of volatility in the stock market and invest in Aurobindo Pharma shares after thorough research. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Marico Q1 Results FY26: Q1 PAT Up 8.62% to ₹504.00 Crore; Revenue Surged 23.31% YoY

Tata Investment Corporation Q1 Results FY26: Q1 PAT Soars 11.62% to ₹146.30 Crore; Revenue Surged 2.11% YoY

Shree Cement Q1 Results FY26: Q1 PAT Surges 130.67% to ₹642.66 Crore; Revenue Surged 3.06% YoY

Escorts Kubota Q1 Results FY26: Q1 PAT Jumps 363.16% to ₹1,397.11 Crore; Revenue Down 2.86% YoY

Knowledge Realty Trust REIT IPO GMP & Review: Apply or Avoid?

BLT Logistics IPO GMP & Review: Apply or Avoid?

RR Kabel Q1 Results FY26: Q1 PAT Jumps 39.44% to ₹89.77 Crore; Revenue Surged 13.85% YoY

Kirlosker Brothers Q1 Results FY26: Q1 PAT Soars 2.46% to ₹66.70 Crore; Revenue Declined 5.03% YoY

Aaradhya Disposal IPO GMP & Review: Apply or Avoid?

Aarti Industries Q1 Results FY26: Q1 PAT Down 68.61% to ₹43.00 Crore; Revenue Declined 9.45% YoY